Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 July 2020 | Story Nonsindiso Qwabe | Photo Supplied
Tau Tladi.

In times of great difficulty, a tale of hope goes a long way in encouraging one to persevere. Tau Tladi, a second-year LLB extended-programme student who was diagnosed with ataxia – a degenerative disease of the nervous system – at a young age, has conquered many adversities. He is living his life to the fullest, pursuing his dream of becoming a lawyer one day. Because of a brain injury during birth, Tladi struggles to speak, write, or walk. On campus, he makes use of a scribe and reader to write his tests and exams. 

Learning from others key to success

“Living with ataxia means I have improper speech, I struggle to walk properly, my hands can’t grab things properly, and I can’t even write with them.   Seeing other people living with disabilities and still pursuing their dreams has inspired me a lot; it made me realise that I too have the ability to achieve my dreams,” he said. 
While this disability presented him with many hindrances in life, it has never held him back. “Growing up was challenging because I was not able to develop like other children. As I got older, I could not experience some of the things that other kids could do, such as playing and running around,” he said.

Triumph in the face of adversity
 
Despite all the challenges, Tau completed his matric in 2016 and was even named as one of the top 100 achievers in the Free State. He describes his admission to the LLB programme as a dream come true. “I have always wanted to study an LLB degree. It is the best feeling ever to be at university and studying something that I always wanted to do. I would love to become an attorney.”

Tladi hopes to finish his degree in 2021. He is also an avid sportsman, having participated in the Free State paracycling team and winning first place at the national competition. 

“Living with disability has never been easy for me, so I have learned to be grateful and use every opportunity that I come across and work very hard to fulfil my dreams.”

Hanlie Grobler, Senior Officer in the Faculty of Law, described Tladi as a remarkable young man who always wears a smile on his face. “If you are feeling a bit blue today, cheated by COVID-19, that life is unfair to you – remember this young man who is an excellent example of determination, and do what you have to do, to the best of your ability, and be thankful for what you have.”

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept